Navigation Links
Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, manufacturing and marketing FavId or Favrille's other product candidates; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using FavId; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward- looking statements contained in this release as a result of new information, future events or otherwise.

CONTACT: Tamara A. Seymour, CFO and Vice President, Finance &Administration, +1-858-526-8035, , or Pete De Spain,Associate Director, Investor Relations & Corporate Communications,+1-858-526-2426, , both of Favrille, Inc. tseymour@favrille.com pdespain@favrille.com

Web site: http://www.favril
'"/>





Page: 1 2 3 4

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... products may protect against inflammation. Such were ... trial on the effects of processed tomatoes on ... men and women, presented by one of the ... 19, 2009 at the Experimental Biology meeting held ...
... Ability of PS-Targeting Antibodies to Reverse the Immune ... Microenvironment and Mobilizing Key Components of the Immune ... Stimulate Dendritic Cell Maturation, Inflammatory Cytokine and Chemokine ... and TUSTIN, Calif., April 21 Peregrine Pharmaceuticals, ...
Cached Medicine Technology:Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting 2Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting 3Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 3Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 4Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 5Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 6Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 7
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
(Date:4/17/2014)... 10 million older Americans suffer from depression, often brought ... new research a project that followed the lives ... found that Internet use among the elderly can ... percent. , "That,s a very strong effect," said Shelia ... studies and media who led the project. "And it ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Feb. 4 Pulse Systems announced today ... the International,Organization for Standardization (ISO) quality systems ... "Achievement of these highly-regarded ... contract manufacturing services to the,medical device industry, ...
... (Nasdaq: KNSY ), a leading medical technology company ... of medical procedures, today announced the resignation of Mr. Jeffrey ... its Board of Directors.Mr. Smith became a director of Kensey ... Corporate Governance and Nominating Committee as well as a member ...
... Oxford, UK, 04 February 2009 The journal ... publication, has announced the winner of the 2008 David ... Persson and Jan van der Linden from the Karolinska ... decrease the risk of surgical site infection" was judged ...
... Md., February 4, 2009 With counterfeit and adulterated ... United States and worldwide, the U.S. Pharmacopeial (USP) Convention ... products that have been involved in episodes of adulteration ... these standards, for the blood thinner heparin and the ...
... EPA/DHA and 170% Daily Requirement of Vitamin EPARAMUS, N.J., Feb. ... today announced that it will launch Smart Balance(TM) Milk in ... and New England during the first quarter of 2009. ... in Florida and Georgia, tastes rich and creamy, is low ...
... in Four Americans Show Features Real People with Real Stories, ... and Denver Broncos, Quarterback Jay CutlerWESTPORT, Conn., Feb. 4 ... new 2009 television schedule for dLifeTV , ... with diabetes, airing every Sunday on CNBC at 7:00PM ET, ...
Cached Medicine News:Health News:Pulse Systems Receives Dual Certification Under ISO 13485:2003 and ISO 9001:2008 2Health News:Kensey Nash Announces Director Resignation 2Health News:USP announces new standards to protect patients from counterfeit and adulterated medicines 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 3Health News:dLifeTV Announces New Season Programming and Celebrity Guests; Only Nationally-Broadcast Program About Diabetes Celebrates 5th Year and 200th Show 2Health News:dLifeTV Announces New Season Programming and Celebrity Guests; Only Nationally-Broadcast Program About Diabetes Celebrates 5th Year and 200th Show 3
... from Richmond Products includes the four demonstration plates, ... series for a total of 24 plates. Each ... easy and clean page selection. The test also ... a laminated copy of the score sheet. The ...
Ishihara 14 plate color vision testing set. Suitable for screening purposes....
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
... BD Edgeahead Stiletto / MVR knife. 1.1 ... insertion of 1.1 mm (19G) Cannula (5/bx, 1 ... knives are consistently sharp and precise. Sure grip ... edge. Tapered tip creates a fluid tight incision ...
Medicine Products: